Processa Pharmaceuticals (PCSA) Q3 2024 earnings summary

Executive summary

• Clinical-stage biopharma focused on next-generation chemotherapy (NGC) drugs, aiming to improve safety and efficacy of cancer treatments using a regulatory science approach.

• Pipeline includes NGC-Cap (Phase 2 initiated for breast cancer, first patient dosed October 2, 2024, with interim data expected H2 2025), NGC-Gem (Phase 2a completed, FDA discussions planned), and NGC-Iri (preclinical, positive data in August 2024), with two non-oncology assets being considered for out-licensing.

• No product revenue; operations funded by equity offerings and ATM sales.

Financial highlights

• Net loss of $3.4M for Q3 2024 ($1.03/share), compared to $2.1M ($1.54/share) in Q3 2023; net loss of $9.12M for nine months ended September 30, 2024.

• Research and development expenses rose to $2.3M in Q3 2024 (up from $1.2M YoY), driven by NGC-Cap clinical activities.

• General and administrative expenses were $1.14M in Q3 2024, up $121K YoY; nine-month G&A expenses decreased by $749K due to lower professional fees and stock-based compensation.

• Cash and cash equivalents at September 30, 2024, were $2.9M, down from $4.7M at year-end 2023.

• Net cash used in operating activities was $9.0M for the nine months ended September 30, 2024.

Outlook and guidance

• Insufficient cash to fund operations for the next twelve months; additional funding required to continue Phase 2 NGC-Cap trial and other pipeline activities.

• Interim data from the NGC-Cap Phase 2 trial expected in the second half of 2025; IND-enabling toxicology studies for NGC-Iri planned for 2025.

• Plans to raise capital through equity, debt, collaborations, or strategic transactions; failure to secure funding may delay or suspend R&D programs.

• Ongoing FDA engagement for NGC-Gem trial design and regulatory pathway.

• No expectation of positive cash flow from operations in the foreseeable future.